Glass N R, Miller D T, Sollinger H W, Belzer F O
Surgery. 1983 Oct;94(4):636-42.
According to an analysis of 100 consecutive kidney transplants from live donors performed at our center over a 25-month period beginning in June 1980, only two patients have died, and five other patients had graft loss from acute or chronic rejection; this resulted in an overall actuarial 2-year patient survival rate of 98% and a graft survival rate of 90%. Eighty-five of the 93 patients with functioning grafts have excellent renal function, with serum creatinine levels less than or equal to 2 mg/dl. Complications occurred in 24 patients but rarely jeopardized the patients' lives or grafts or resulted in permanent disability. The functional capacity of most of the patients was improved by transplantation or was excellent both before and after transplantation. Forty-three transplants were possible through the use of the original or Imuran-modified donor-specific transfusion protocol, so that the lack of compatible donors rarely limited the availability of this therapy. New therapies that might improve graft or patient survival rate cannot reasonably be evaluated in recipients of live donor kidney transplants, because these results are already good. We have estimated that as much as $3.6 million in health care funds could be saved every 2 years at our center if we offered kidney transplants from healthy willing donors to all recipients before instituting dialysis. From our study we conclude that live donor kidney transplantation is an available, highly effective, and cost-efficient form of therapy for patients with end-stage renal disease.
根据对1980年6月开始的25个月期间在我们中心进行的100例连续活体供肾移植的分析,只有两名患者死亡,另外五名患者因急性或慢性排斥反应导致移植肾丧失;这使得患者2年实际生存率总体为98%,移植肾生存率为90%。93例移植肾功能良好的患者中有85例肾功能极佳,血清肌酐水平小于或等于2mg/dl。24例患者出现并发症,但很少危及患者生命、移植肾或导致永久性残疾。大多数患者的功能能力通过移植得到改善,或在移植前后均极佳。通过使用原始的或硫唑嘌呤改良的供者特异性输血方案,43例移植得以进行,因此缺乏匹配供者很少限制这种治疗方法的可用性。由于活体供肾移植的结果已经很好,所以新的可能改善移植肾或患者生存率的治疗方法在活体供肾移植受者中无法得到合理评估。我们估计,如果在开始透析之前为所有受者提供来自健康自愿供者的肾移植,我们中心每两年可节省高达360万美元的医疗保健资金。从我们的研究中我们得出结论,活体供肾移植对于终末期肾病患者是一种可行、高效且具有成本效益的治疗方式。